lactobacillus reuteri
Place in Therapy
Place in Therapy
The pathophysiology and etiology of infantile colic is a mystery. Several studies have been done and
many mechanisms proposed. One such mechanism is an imbalance of colon bacteria in colicky infants.
Results of the three published randomized controlled trials published to date demonstrate efficacy of
Lactobacillus reuteri in treating healthy, term, breastfed infants with symptoms of infantile colic. These
trials show a reduction in overall crying time as soon as one week after the initiation of Lactobacillus
reuteri. Furthermore, these trials show no association of Lactobacillus reuteri with adverse events.
Although limited data is available, the efficacy and safety of L reuteri compared to other treatment
options for infantile colic is excellent. For this reason, it has been selected as the first-line treatment of
infantile colic.
References:
1. Savino F, Pelle E, Palumeri E, Oggero R, Miniero R. Lactobacillus reuteri (american type culture collection strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 2007 Jan;119(1):e124—30.
2. Savino F, Cordisco L, Tarasco V, Palumeri E, Calabrese R, Oggero R, Roos S et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics 2010 Sept;126(3):e526-33.
3. Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the Management of Infantile Colic in Breastfed Infants: A randomized, double-blind, placebo-controlled trial. J Pediatr. 2013 Feb;162(2):257-62.
4. Thomas DW, Greer FR, Committee on nutrition; section on gastroenterology, hepatology, and nutrition. Clinical Report – Probiotics and Prebiotics in Pediatrics. Pediatrics 2010;126:1217-31.
The pathophysiology and etiology of infantile colic is a mystery. Several studies have been done and
many mechanisms proposed. One such mechanism is an imbalance of colon bacteria in colicky infants.
Results of the three published randomized controlled trials published to date demonstrate efficacy of
Lactobacillus reuteri in treating healthy, term, breastfed infants with symptoms of infantile colic. These
trials show a reduction in overall crying time as soon as one week after the initiation of Lactobacillus
reuteri. Furthermore, these trials show no association of Lactobacillus reuteri with adverse events.
Although limited data is available, the efficacy and safety of L reuteri compared to other treatment
options for infantile colic is excellent. For this reason, it has been selected as the first-line treatment of
infantile colic.
References:
1. Savino F, Pelle E, Palumeri E, Oggero R, Miniero R. Lactobacillus reuteri (american type culture collection strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 2007 Jan;119(1):e124—30.
2. Savino F, Cordisco L, Tarasco V, Palumeri E, Calabrese R, Oggero R, Roos S et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics 2010 Sept;126(3):e526-33.
3. Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the Management of Infantile Colic in Breastfed Infants: A randomized, double-blind, placebo-controlled trial. J Pediatr. 2013 Feb;162(2):257-62.
4. Thomas DW, Greer FR, Committee on nutrition; section on gastroenterology, hepatology, and nutrition. Clinical Report – Probiotics and Prebiotics in Pediatrics. Pediatrics 2010;126:1217-31.